Get the Stockscreener App
1.74
1.14%
-0.02
Pre-market:
1.71
-0.03
-1.72%
Pyxis Oncology Inc stock is traded at $1.74, with a volume of 650.02K.
It is down -1.14% in the last 24 hours and down -23.68% over the past month.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
See More
Previous Close:
$1.76
Open:
$1.76
24h Volume:
650.02K
Relative Volume:
1.35
Market Cap:
$110.24M
Revenue:
$13.86M
Net Income/Loss:
$-81.74M
P/E Ratio:
-1.3348
EPS:
-1.3036
Net Cash Flow:
$-66.98M
1W Performance:
+2.96%
1M Performance:
-23.68%
6M Performance:
-58.57%
1Y Performance:
+45.00%
1-Day Range:
$1.66
$1.83
1-Week Range:
$1.54
$1.87
52-Week Range:
$0.97
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.74 | 110.24M | 13.86M | -81.74M | -66.98M | -1.3036 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
Pyxis Oncology elects directors and ratifies auditor at annual meeting - Investing.com
Pyxis Oncology elects directors and ratifies auditor at annual meeting By Investing.com - Investing.com UK
Pyxis Oncology Stockholders Approve Directors and Auditor Slate - TipRanks
Pyxis Oncology (PYXS) shareholders elect Class II directors and ratify Ernst & Young as 2026 auditor - Stock Titan
Pyxis Oncology Inc. (PYXS) Q1 2026 Earnings: Narrower Loss Beats Estimates as Stock Rises on Clinical Progress - newsline.com
PYXIS ONCOLOGY INC (PYXS) Stock Price & Overview - ChartMill
Analysts See Nearly 3X Upside in Pyxis Oncology (PYXS) - Insider Monkey
PYXS Q1 2026 Earnings: Narrower-Than-Expected Loss Supports Stock UptickEarnings Quality Analysis - newsline.com
Number of shareholders of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Pyxis Oncology, Inc. - MLQ.ai
Pyxis Oncology Stock Draws Attention Again After Jefferies as Traders Eye MICVO Results - Bez Kabli
PYXS: Mid-year data will clarify MICVO's efficacy, safety, and pivotal trial path in head and neck cancer - TradingView
HC Wainwright & Co. maintains Pyxis Oncology (PYXS) buy recommendation - MSN
PYXS: Mid-year data will highlight MICVO's efficacy and safety in head and neck cancer, supporting pivotal plans - TradingView
Pyxis Oncology Inc. (PYXS) Q1 2026 Earnings: Narrower-than-expected loss as clinical pipeline advancesProfit Guidance Range - newsline.com
Pyxis Oncology (PYXS) Holds Steady at $1.80 as Biotech Sector Watches Key LevelsDealer Gamma - newsline.com
PYXS News | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill
Pyxis Oncology Edges Higher as Shares Test Key Resistance LevelsUnusual Put Volume - The Legal Advocate
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
PYXS Q1 2026 Earnings: Better-than-Expected Loss Highlights Progress in Oncology PipelinePeak Earnings Alert - newsline.com
Pyxis Oncology Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ReactionEarnings Surprise Report - The Legal Advocate
PYXS: MICVO demonstrates high efficacy and improved safety in head and neck cancer with dose capping - TradingView
Pyxis Oncology (PYXS) Rating Reiterated as Buy by HC Wainwright & Co. | PYXS Stock News - GuruFocus
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Raises Target Price to $6 - Moomoo
RBC Capital Keeps Their Buy Rating on Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology (PYXS) Gets a Buy from Guggenheim - The Globe and Mail
Wedbush Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $5 to $7 - Moomoo
Pyxis Oncology, Inc. Faces Substantial Doubt as a Going Concern and Requires Additional Capital – 2026 Q1 Financial Report Highlights Risks and Challenges 25 – Minichart - Minichart
Pyxis Oncology Faces Urgent Capital Needs and Potential Dilution Risks Amid Market Volatility - TipRanks
Pyxis Oncology Shares Slide on Steeper 1Q Loss - Moomoo
Pyxis Oncology Reports Q1 2026 Financial Results and Advances MICVO ADC Toward Key Clinical Milestones in Head and Neck Cancer - Minichart
Pyxis Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Pyxis Oncology stock (US70611B1026): Q1 2026 loss widens to $23.3M - AD HOC NEWS
Pyxis Oncology (PYXS) Q1 2026 loss deepens as MICVO trials expand and cash runway tightens - Stock Titan
Pyxis Oncology (PYXS) posts $23.3M Q1 loss and advances MICVO trials - Stock Titan
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones - marketscreener.com
BRIEF-Pyxis Oncology Q1 Net Income USD -23.272 Million - TradingView
Pyxis Oncology Reports First Quarter 2026 Financial Results - GlobeNewswire
Should You Sell Pyxis Oncology (PYXS) After -18.89% Drop? 2026-05-14Viral Trades - newser.com
Pyxis Oncology to Participate in Upcoming Investor Conferences - Caledonian Record
Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - MSN
Pyxis Oncology stock (US70611B1026): Builds $540M cash pile after Q1 loss - AD HOC NEWS
Pyxis Oncology Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
TradingKey - TradingKey
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer - The Manila Times
SEC EDGAR Submission 0000950170-23-023950 - SEC.gov
Pyxis brings in former ImmunoGen dealmaker to advance MICVO - Stock Titan
Wedbush Initiates Pyxis Oncology at Outperform With $6 Price Target - marketscreener.com
Wedbush initiated coverage on Pyxis Oncology with a new price target - Quantisnow
Wedbush Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $6 - Moomoo
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):